
Peking University First Hospital has a total capacity of 1,805 beds across three campuses: Central, Miyun, and Daxing. The hospital delivers a full range of inpatient and outpatient services, serving patients across China and internationally.
Established in 1915, Peking University First Hospital (PUFH) is one of China's most prestigious medical institutions, affiliated with the Peking University Health Science Center. As a top-tier tertiary hospital classified as Grade 3A, it is recognized for its leadership in clinical excellence, education, and research. Over the decades, PUFH has been pioneering in shaping modern Chinese medicine, particularly in specialties such as urology, nephrology, pediatrics, neurology, cardiology, and organ transplantation.
The hospital is home to a team of highly qualified doctors and professors, including many national-level experts. Known for managing complex and rare diseases, it continues to advance patient care through innovation, multidisciplinary collaboration, and compassionate treatment.
Advanced Technology & Facilities
Key Services at Peking University First Hospital
Peking University First Hospital blends a century of medical heritage with high-quality clinical care, innovative research, and comprehensive education. It stands as a benchmark of excellence in China, committed to improving patient outcomes through multidisciplinary collaboration and compassionate, personalized care.

The hospital has approximately 50 inpatient beds in its main campus, along with nine satellite clinics across Beijing. It manages over 2,500 outpatient visits each week and provides care to hundreds of thousands of patients annually, both local and international.
Beijing United Family Hospital (BJU) is one of China’s most prestigious private medical institutions, known for delivering world-class healthcare that meets international standards. Established in 1997, it was the first foreign-invested hospital in China and has since become a trusted choice for both International and Chinese patients seeking high-quality, patient-focused care. As part of the United Family Healthcare network, BJU has built a reputation for medical excellence, advanced technology, and a uniquely personalized approach to treatment.
The hospital is staffed by a diverse team of internationally trained doctors, many of whom have practiced in top healthcare systems across the U.S., Europe, and Asia. This global expertise is complemented by the latest medical equipment, multilingual support services, and a strong commitment to clinical safety and patient satisfaction. Recognized by the Joint Commission International (JCI) for meeting the highest standards in healthcare delivery, BJU offers a full spectrum of medical services across numerous specialties, including family medicine, internal medicine, orthopedics, oncology, cardiology, obstetrics, pediatrics, and plastic surgery.
Advanced Technology & Facilities
Key Services at BJU
Beijing United Family Hospital stands as a pioneer in international-standard healthcare in China, blending modern technology, world-class medical expertise, and a warm, comprehensive approach to family health.

As part of Singapore‑listed Raffles Medical Group, founded in 1976, RMG China operates 5 tertiary hospitals and over 100 clinics, supported by 430+ physicians and 900+ nurses & allied health professionals, delivering comprehensive inpatient and outpatient services.
Raffles Medical Group has operated in China since 2010, growing into a trusted name among both local and expatriate communities. All RMG China hospitals and clinics follow the Group’s Institutional Group Practice Model, which emphasizes integrated, peer-reviewed, and clinically audited care. Backed by Raffles Hospital Singapore, accredited by Joint Commission International (JCI), the network ensures alignment with global standards for quality and patient safety. With a rigorous clinical governance framework, strategic insurance and corporate partnerships, and a presence in key Chinese cities, RMG serves over 2.8 million patients annually. The Group continues to expand across China, offering world-class healthcare that combines international expertise with localized, patient-centered care.
Advanced Technology & Facilities
Key Services at Raffles Medical Group China
Raffles Medical Group China is a leading integrated private hospital network, delivering high-quality, multidisciplinary medical care in major Chinese cities. With its robust institutional infrastructure, advanced diagnostic and treatment facilities, and a reputation anchored by the Singapore-based Raffles Hospital, RMG China continues to expand and uphold global healthcare standards.

GoBroad Healthcare Group, founded in 2017, is a leading medical network in China, specializing in the treatment of complex hematologic diseases and solid tumors. The group integrates clinical treatment, research, reference laboratories, and medical information technology under an Academic Research Organization model. With seven hospitals across Beijing, Shanghai, and Guangzhou, it provides advanced therapies including CAR-T cell therapy, hematopoietic stem cell transplantation, chemotherapy, radiotherapy, and targeted therapy. Its multidisciplinary teams ensure that patients receive comprehensive and personalized treatment for both common and rare conditions. The group is known for its patient-centered approach by combining modern medical science with innovative therapies and long-term follow-up care. With international collaborations, multilingual staff, and dedicated global patient services, it has become a trusted choice for individuals seeking specialized cancer and hematology treatments in China. By focusing on research-driven medicine, advanced facilities, and supportive care, GoBroad Healthcare Group continues to enhance patient survival, recovery, and long-term quality of life.
Advanced Technology & Facilities
Key Services



China has become an important center for Car NK therapy research and early clinical application, supported by large academic hospitals and close collaboration between clinicians and biotechnology teams. Clinics offering this treatment typically have specialists trained in hematology, oncology, and cellular immunotherapy, with experience managing complex cancers that may not respond to standard therapies. Advanced laboratory infrastructure supports cell engineering, quality control, and monitored infusion pathways.
Car NK therapy in China typically ranges from USD 35,000 to USD 90,000. Costs vary based on the type of cell product used, whether treatment is part of a clinical program, length of hospital stay, and the level of supportive care required. Recovery is often described using milestone based patterns. During the first week, patients are closely monitored in hospital. Over the first month, follow up visits focus on immune response and symptom changes before patients return to more regular routines. Not every patient is an ideal candidate, so each case requires individual assessment and a tailored treatment plan by the clinic team.
This information is for educational purposes and does not replace an in person consultation with a qualified specialist.
Clinics providing Car NK therapy in China generally operate within major teaching hospitals and follow structured patient pathways. These centers emphasize safety standards, clean clinical environments, and coordinated care between laboratory teams and treating physicians. Patient selection, consent, and monitoring protocols are carefully documented due to the investigational nature of many Car NK approaches.
Shanghai Changzheng Hospital runs a Car NK cell therapy clinical program that explores advanced engineered NK cell products, including iPSC derived Car NK therapies. The hospital is known for investigator initiated trials that evaluate new treatments for advanced cancers such as small cell lung cancer. Its multidisciplinary teams focus on patient eligibility screening, safety monitoring, and structured follow up during and after infusion.
Shanghai Chest Hospital, also known as Shanghai Pulmonary Hospital, serves as a trial site for iPSC Car NK cell therapy. The hospital conducts early phase programs targeting lung related cancers, with a strong emphasis on managing risks such as immune reactions and variable treatment response. Their approach includes detailed baseline evaluation, inpatient observation, and scheduled follow up visits to monitor outcomes and safety signals.
Best Clinic Abroad supports international patients who are considering Car NK therapy in China. The team helps connect you with vetted clinics, clarify available options, and coordinate key details around your treatment stay.
➤ Initial virtual consultation - Arrange an online discussion so clinics can review medical history and assess candidacy.
➤ Clear package information - Request transparent price ranges and explanations of what is included in treatment programs.
➤ Medical file coordination - Organize pathology reports, imaging, and prior treatment records for clinic review.
If you are exploring Car NK therapy in China, you can start by sharing your case with Best Clinic Abroad and receive guided support in choosing a suitable clinic and planning your next steps.
Question: Who is usually considered an ideal candidate for Car NK therapy
Answer: Candidates are typically patients with certain cancers who have limited response to standard treatments, but eligibility depends on diagnosis, prior therapy, and overall health.
Question: What are common risks associated with Car NK therapy
Answer: Potential risks include immune reactions or uncertain effectiveness, which clinics manage through screening, inpatient monitoring, and structured follow up care.